Disease Overview：Chronic gastritis（CG）
Chronic gastritis is a persistent inflammatory condition of the gastric mucosa, commonly caused by Helicobacter pylori infection, long-term use of NSAIDs, autoimmune mechanisms, or bile reflux. It may present with nonspecific symptoms—including epigastric discomfort, early satiety, nausea, and bloating—or remain asymptomatic until complications such as atrophic gastritis, intestinal metaplasia, or increased risk of gastric adenocarcinoma develop. Diagnosis relies on upper gastrointestinal endoscopy with targeted biopsies, histopathological evaluation (e.g., Sydney System grading), and ancillary tests including H. pylori urea breath testing or stool antigen assays. Management emphasizes etiology-specific interventions: eradication therapy for H. pylori (typically quadruple regimens), acid suppression with proton pump inhibitors, mucosal protectants, and lifestyle modification. Long-term surveillance is recommended in high-risk subtypes, particularly those with atrophy or metaplasia.
China offers distinct advantages for chronic gastritis management: its digestive disease specialists—many trained internationally and affiliated with tier-1 hospitals like Peking Union Medical College Hospital and Ruijin Hospital—apply evidence-based, individualized protocols aligned with global guidelines (ACG, AASLD). Advanced endoscopic platforms (e.g., high-definition NBI, confocal laser endomicroscopy) enable precise mucosal assessment and real-time histologic prediction. Clinical outcomes reflect this capability: over 92% H. pylori eradication rates in recent multicenter studies, with low recurrence through tailored follow-up. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising diagnostic rigor or therapeutic standards. As a dedicated medical tourism agency, we facilitate seamless care for international patients—vetting accredited hospitals, coordinating appointments with gastroenterology specialists, clarifying all-inclusive pricing upfront, and providing end-to-end support from visa assistance to post-treatment teleconsultation.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Chronic Gastritis (Gastroenterology)
Non-Surgical / Conservative Management
*Target Criteria:* Confirmed diagnosis via endoscopy + biopsy; *H. pylori* status determined; no severe complications (e.g., strictures, malignancy).
- •First-Line Medication Therapy
• Drug cost (generic, hospital pharmacy): $28–$42 - *Acid Suppression (PPI monotherapy, 8 weeks):* Esomeprazole 20 mg daily • Drug cost: $12–$20 - *Mucosal Protection:* Sucralfate 1 g QID × 4 weeks • Drug cost: $15–$25
- •Diagnostic & Monitoring Fees (Per Episode)
• *H. pylori* testing (urea breath test or stool antigen): $18–$32 • Complete blood count + ferritin + vitamin B12: $24–$38 • Serum pepsinogen I/II + gastrin-17 (for atrophic gastritis staging): $65–$95
Surgical / Procedural Interventions
*Eligibility Criteria:* Refractory symptoms with documented pre-neoplastic lesions (e.g., intestinal metaplasia/dysplasia); confirmed high-grade dysplasia on ≥2 biopsies; contraindications to endoscopic resection.
- •Endoscopic Submucosal Dissection (ESD) for Dysplasia
• Preoperative workup (EKG, chest X-ray, coagulation panel, cardiac echo if >65 yrs): $110–$175
- •Surgical Gastrectomy (Rare, only for carcinoma-in-situ or invasive cancer)
• Preoperative staging (abdominal CT + EUS): $290–$410
Special / Complex Condition Management
- •Autoimmune Gastritis (with pernicious anemia):
• Annual surveillance endoscopy + extended biopsies: $260–$340/visit
- •Refractory Gastritis with NSAID-induced ulceration:
Quick Selection Guide
- •Young adult (<45), *H. pylori*+, mild symptoms: Start quadruple therapy ($28–$42) + urea breath test ($18) — *total first-line investment: <$70*.
- •Middle-aged (45–65), atrophic gastritis, low income: Prioritize pepsinogen testing ($65) + annual endoscopy ($260) over repeated drug trials.
- •Elderly (>75) with comorbidities (COPD, CKD): Avoid bismuth/metronidazole; use PPI + sucralfate ($35–$45/month) + B12 monitoring ($24 lab panel).
- •High-grade dysplasia confirmed: Proceed directly to ESD ($1,450–$2,100) — *cost-effective vs. delayed cancer surgery*.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Chronic gastritis Medical Vacation Packages
Curated transparent all-inclusive packages combining Chronic gastritis treatment with China top medical destinations:
